 | Up a level |
Stathis, Anastasios; Pirosa, Maria Cristina; Orsucci, Lorella; Feugier, Pierre; Tani, Monica; Ghesquières, Hervé; Musuraca, Gerardo; Rossi, Francesca Gaia; Merli, Francesco; Guièze, Romain; Gyan, Emmanuel; Gini, Guido; Marino, Dario; Gressin, Remy; Morschhauser, Franck; Cavallo, Federica; Palombi, Francesca; Conconi, Annarita; Tessoulin, Benoît; Tilly, Hervé; ... (2024). IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. Haematologica - the hematology journal, 109(8), pp. 2564-2573. Ferrata-Storti Foundation 10.3324/haematol.2023.283918
Pabst, Thomas; Papayannidis, Cristina; Demirkan, Fatih; Doronin, Vadim; Fogliatto, Laura M; Guttke, Christina; Gyan, Emmanuel; Hamad, Nada; Herrera, Pilar; Hultberg, Anna; Jacobs, Julie; Johnson, Amy J; Langlois, Angélique; Ma, Xuewen; Martinelli, Giovanni; Arnan, Montserrat; Müller, Rouven; Nottage, Kerri; Ofran, Yishai; Özcan, Muhit; ... (2023). Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study. The Lancet. Haematology, 10(11), e902-e912. Elsevier 10.1016/S2352-3026(23)00207-7
